Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 3Carcinoma, Hepatocellular 2Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biochemically Recurrent Prostate Carcinoma 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Temozolomide 41Radiotherapy 19Radiation 12Nivolumab 10pembrolizumab 8Magnetic Resonance Spectroscopy 8Bevacizumab 7Specimen Handling 6poly ICLC 4atezolizumab 4Lomustine 4Ipilimumab 4Surgical Procedures, Operative 3Photons 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3veliparib 2sargramostim 2rocakinogene sifuplasmid 2olaparib 2niraparib 2Transurethral Resection of Bladder 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2OKN 007 2Mycophenolic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Glioblastoma × Photons × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02179086 2026-01-14

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2 Active not recruiting
606 enrolled
CNS

Glioblastoma

NCT03587038 2025-12-10

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

University of Oklahoma

Phase 1 Active not recruiting
27 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡